Suppr超能文献

AA淀粉样变性患者的临床结局与生存情况

Clinical outcomes and survival in AA amyloidosis patients.

作者信息

Ayar Yavuz, Ersoy Alparslan, Oksuz Mustafa Ferhat, Ocakoglu Gokhan, Vuruskan Berna Aytac, Yildiz Abdülmecit, Isiktas Emel, Oruc Aysegül, Celikci Sedat, Arslan Ismail, Sahin Ahmet Bilgehan, Güllülü Mustafa

机构信息

Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey.

Uludağ University Faculty of Medicine, Department of Nephrology, Bursa, Turkey.

出版信息

Rev Bras Reumatol Engl Ed. 2017 Nov-Dec;57(6):535-544. doi: 10.1016/j.rbre.2017.02.002. Epub 2017 Mar 23.

Abstract

AIM

Amyloid A amyloidosis is a rare complication of chronic inflammatory conditions. Most patients with amyloid A amyloidosis present with nephropathy and it leads to renal failure and death. We studied clinical characteristics and survival in patients with amyloid A amyloidosis.

METHODS

A total of 81 patients (51 males, 30 females) with renal biopsy proven amyloid A amyloidosis were analyzed retrospectively. The patients were divided into good and poor outcomes groups according to survival results.

RESULTS

Most of the patients (55.6%) had nephrotic range proteinuria at diagnosis. Most frequent underlying disorders were familial Mediterranean fever (21.2%) and rheumatoid arthritis (10.6%) in the good outcome group and malignancy (20%) in the poor outcome group. Only diastolic blood pressure in the good outcome group and phosphorus level in the poor outcome group was higher. Serum creatinine levels increased after treatment in both groups, while proteinuria in the good outcome group decreased. Increase in serum creatinine and decrease in estimated glomerular filtration rate of the poor outcome group were more significant in the good outcome group. At the time of diagnosis 18.5% and 27.2% of all patients had advanced chronic kidney disease (stage 4 and 5, respectively). Median duration of renal survival was 65±3.54 months. Among all patients, 27.1% were started dialysis treatment during the follow-up period and 7.4% of all patients underwent kidney transplantation. Higher levels of systolic blood pressure [hazard ratios 1.03, 95% confidence interval: 1-1.06, p=0.036], serum creatinine (hazard ratios 1.25, 95% confidence interval: 1.07-1.46, p=0.006) and urinary protein excretion (hazard ratios 1.08, 95% confidence interval: 1.01-1.16, p=0.027) were predictors of end-stage renal disease. Median survival of patients with organ involvement was 50.3±16 months.

CONCLUSION

Our study indicated that familial Mediterranean fever constituted a large proportion of cases and increased number of patients with idiopathic amyloid A amyloidosis. Additionally, it was observed that patient survival was not affected by different etiological causes in amyloid A amyloidosis.

摘要

目的

淀粉样蛋白A淀粉样变性是慢性炎症性疾病的一种罕见并发症。大多数淀粉样蛋白A淀粉样变性患者表现为肾病,最终导致肾衰竭和死亡。我们研究了淀粉样蛋白A淀粉样变性患者的临床特征和生存率。

方法

对81例经肾活检证实为淀粉样蛋白A淀粉样变性的患者(51例男性,30例女性)进行回顾性分析。根据生存结果将患者分为预后良好组和预后不良组。

结果

大多数患者(55.6%)在诊断时出现肾病范围的蛋白尿。预后良好组最常见的潜在疾病是家族性地中海热(21.2%)和类风湿关节炎(10.6%),预后不良组为恶性肿瘤(20%)。仅预后良好组的舒张压和预后不良组的磷水平较高。两组治疗后血清肌酐水平均升高,而预后良好组的蛋白尿减少。预后不良组血清肌酐的升高和估计肾小球滤过率的降低在预后良好组中更为显著。诊断时,所有患者中有18.5%和27.2%患有晚期慢性肾脏病(分别为4期和5期)。肾脏生存的中位持续时间为65±3.54个月。在所有患者中,27.1%在随访期间开始透析治疗,7.4%的患者接受了肾移植。收缩压水平较高[风险比1.03,95%置信区间:1 - 1.06,p = 0.036]、血清肌酐(风险比1.25,95%置信区间:1.07 - 1.46,p = 0.006)和尿蛋白排泄量(风险比1.08,95%置信区间:1.01 - 1.16,p = 0.027)是终末期肾病的预测指标。器官受累患者的中位生存期为50.3±16个月。

结论

我们的研究表明,家族性地中海热在病例中占很大比例,特发性淀粉样蛋白A淀粉样变性患者数量增加。此外,观察到淀粉样蛋白A淀粉样变性患者的生存不受不同病因的影响。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验